What is TESARO's stock symbol?
TESARO trades on the NASDAQ under the ticker symbol "TSRO."
Where is TESARO's stock going? Where will TESARO's stock price be in 2017?
17 brokerages have issued 12 month price objectives for TESARO's stock. Their forecasts range from $80.00 to $232.00. On average, they expect TESARO's share price to reach $164.93 in the next year.
When will TESARO announce their earnings?
TESARO is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.
What are analysts saying about TESARO stock?
Here are some recent quotes from research analysts about TESARO stock:
According to Zacks Investment Research, "Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company's product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts. " (10/11/2016)
Credit Suisse Group analysts commented, "Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0 percent POS for now but we conservatively see at least another $1 billion in sales from PARP expansion," analyst Alethia Young wrote in a note."For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50–75 percent and R&D synergies of 15–30 percent. In our base case TSRO P&L we model a tax rate of 30 percent so there could be synergies here as well," Young added.Young also sees further upside to valuation in the long-term from:"PARP expansion in other platinum sensitive tumors."Potential HRD- sales in 1L as we expect the company will amend the protocol."Readouts in breast cancer PARP studies in '17."Immuno-oncology where we expect early data over 2017." (10/10/2016)
Wedbush analysts commented, "sees the clinical benefit of niraparib in HRD-negative patients as likely leading to approval in the entire platinum-sensitive ovarian market."Waltham, Massachusetts-based TESARO, has an approved product in Varubi (rolapitant) for the prevention of delayed nausea and vomiting associated with emetogenic chemotherapy. The company is also developing its Phase 3 asset, niraparib, a PARP inhibitor in ovarian and breast cancer indications.TESARO said it would file NDA and MAA for all patients with recurrent, platinum-sensitive ovarian cancer in the fourth quarter 2016."[W]e see the lack of requirement for a companion diagnostic for niraparib in these patients as a potential advantage over competing PARP inhibitors," analyst David Nierengarten wrote in a note.Related Link: 16 Stocks Moving In Monday's Pre-Market SessionNierengarten, who expects niraparib to be launched in the United States in mid-2017, now assumes 50 percent peak penetration into the platinum-sensitive market (up from 20 percent) and cuts peak penetration into the platinum-resistant market to 15 percent from a previous 25 percent."These changes raise our 2021 niraparib sales estimate to $2.2 billion (from $1.6 billion), which also includes revenues from metastatic breast cancer gBRCAmut patients," Nierengarten highlighted.The analyst says 50 percent peak market share is achievable given the favorable comparison of niraparib with data from olaparib-treated patients and olaparib being limited to gBRCA patients only. Nierengarten also noted niraparib has first-mover advantage in this treatment setting versus rucaparib."Underwhelming data from rucaparib in the third line setting presented at ESMO gives us greater confidence that niraparib will be the market leader in the earlier line of therapy, especially if a companion diagnostic is required," (10/10/2016)
Citigroup Inc. analysts commented, "now more confident about Niraparib approval in ovarian cancer and reimbursement."The 16.3 percent upside is based on the stock's June 29 closing price of $77.40 when the company announced that Niraparib significantly improved progression-free survival for patients with ovarian cancer in a late stage study. "We now see adjusted peak PARP revenues at $800 million vs. $450 million previously as we conservatively increase duration, increase penetration among HRD+ve pts and assign higher probability to HRD +ve ovarian and breast cancer (only gBRCA) revenues," (7/1/2016)
Who owns TESARO stock?
TESARO's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (15.51%), Franklin Resources Inc. (5.89%), Interwest Venture Management Co. (3.91%), State Street Corp (1.91%), Janus Capital Management LLC (1.48%) and Perceptive Advisors LLC (1.33%). Company insiders that own TESARO stock include Arnold L Oronsky, Edward C English, Enterprise Associates 13 L New, James O Armitage, Jeffrey H Hanke and Martin H Jr Huber.
Who sold TESARO stock? Who is selling TESARO stock?
TESARO's stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, State Street Corp, Deerfield Management Co., Asset Management One Co. Ltd., Nicholas Investment Partners LP, Guggenheim Capital LLC, Marshall Wace LLP and Fred Alger Management Inc.. Company insiders that have sold TESARO stock in the last year include Edward C English, Jeffrey H Hanke and Martin H Jr Huber.
Who bought TESARO stock? Who is buying TESARO stock?
TESARO's stock was purchased by a variety of institutional investors in the last quarter, including Interwest Venture Management Co., Perceptive Advisors LLC, Franklin Resources Inc., FMR LLC, Alyeska Investment Group L.P., Castleark Management LLC, Janus Capital Management LLC and Orbimed Advisors LLC. Company insiders that have bought TESARO stock in the last two years include Arnold L Oronsky, Enterprise Associates 13 L New and James O Armitage.
How do I buy TESARO stock?
Shares of TESARO can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of TESARO stock cost?
One share of TESARO stock can currently be purchased for approximately $190.36.